Is the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy?

Basit Öğe Kaydı
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorEr, Muhammed Muhiddin
dc.contributor.authorKocak, Mehmet Zahid
dc.contributor.authorDemirkiran, Aykut
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorAraz, Murat
dc.date.accessioned2024-02-23T13:59:46Z
dc.date.available2024-02-23T13:59:46Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractPurpose The prognostic nutritional index (PNI), like other systemic inflammatory markers, has been shown to be a prognostic factor in various cancer patients. In this study, we aimed to show whether PNI calculated before adjuvant chemotherapy is a prognostic factor for overall survival (OS) and disease-free survival (DFS) in patients with lymph node-positive stage II-III gastric cancer.Methods The PNI was calculated using the albumin and lymphocyte count. The PNI cut-off value was found to be 39.5. They were divided into two groups as being = 39.5 (PNI low group) and > 39.5 (PNI high group).Results Our study included 168 patients with lymph node-positive stage II-III gastric cancer who received adjuvant chemotherapy. Of the patients, 116 (69.0%) were 65 years or younger, and 52 (31.0%) were over 65 years old. Of the patients, 117 (69.6%) were pT3, 51 (30.4%) were pT4. Seventy-three (43.4%) patients had pN1-2 disease and 95 (56.6%) patients had pN3 disease. The number of stage II patients was 73 (43.5%) and the number of stage III patients was 95 (56.5%). There were 73 patients with PNI = 39.5 and 95 patients with PNI > 39.5. The mOS of the patients with low PNI group was 39.5 months, while the OS of the patients with high PNI group was 96.8 months (p = 0.002). In the group of patients with PNI low group, mDFS 24.4 months was significantly higher than those with PNI high group was 50.7 months (p = 0.021). The PNI score was statistically significant in univariate and multivariate analyzes for both DFS and OS.Conclusion PNI can be used as an independent prognostic factor for both OS and DFS in patients lymph node-positive, stage II-III gastric cancer who will receive adjuvant chemotherapy.en_US
dc.identifier.doi10.1007/s12029-023-00972-x
dc.identifier.endpage969en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue3en_US
dc.identifier.pmid37737437en_US
dc.identifier.scopus2-s2.0-85171802728en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage962en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-023-00972-x
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11320
dc.identifier.volume54en_US
dc.identifier.wosWOS:001071669100001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectGastric Canceren_US
dc.subjectPrognostic Nutritional Indexen_US
dc.subjectSurvivalen_US
dc.titleIs the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu